Pharma Mar, S.A. (PHMMF)
USD 81.07
(0.0%)
USD 81.07
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -16.65 Million EUR | 84.46% |
| 2022 | -107.18 Million EUR | -67.43% |
| 2021 | -64.01 Million EUR | -61.88% |
| 2020 | -39.54 Million EUR | -157.75% |
| 2019 | 68.47 Million EUR | -3.09% |
| 2018 | 70.66 Million EUR | -6.92% |
| 2017 | 75.91 Million EUR | -6.51% |
| 2016 | 81.19 Million EUR | -5.55% |
| 2015 | 85.97 Million EUR | 14.76% |
| 2014 | 74.91 Million EUR | 4.33% |
| 2013 | 71.81 Million EUR | -27.03% |
| 2012 | 98.41 Million EUR | -6.6% |
| 2011 | 105.36 Million EUR | -2.08% |
| 2010 | 107.6 Million EUR | 23.35% |
| 2009 | 87.23 Million EUR | 330.73% |
| 2008 | -37.8 Million EUR | -153.81% |
| 2007 | -14.89 Million EUR | -12.68% |
| 2006 | -13.22 Million EUR | -153.76% |
| 2005 | 24.59 Million EUR | -10.98% |
| 2004 | 27.62 Million EUR | 164.27% |
| 2003 | -42.98 Million EUR | 55.34% |
| 2002 | -96.23 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 1.04 Million EUR | -81.68% |
| 2024 Q1 | 4.55 Million EUR | 127.32% |
| 2024 Q2 | 20.06 Million EUR | 340.87% |
| 2023 Q4 | -16.65 Million EUR | 36.9% |
| 2023 Q2 | -32.39 Million EUR | 57.56% |
| 2023 Q3 | -26.39 Million EUR | 18.51% |
| 2023 Q1 | -76.32 Million EUR | 28.79% |
| 2023 FY | -16.65 Million EUR | 84.46% |
| 2022 Q3 | -87.01 Million EUR | 11.3% |
| 2022 Q4 | -107.18 Million EUR | -23.18% |
| 2022 FY | -107.18 Million EUR | -67.43% |
| 2022 Q1 | -104.55 Million EUR | -63.33% |
| 2022 Q2 | -98.1 Million EUR | 6.17% |
| 2021 Q4 | -64.01 Million EUR | 17.57% |
| 2021 FY | -64.01 Million EUR | -61.88% |
| 2021 Q2 | -72.35 Million EUR | -39.03% |
| 2021 Q1 | -52.04 Million EUR | -31.61% |
| 2021 Q3 | -77.66 Million EUR | -7.33% |
| 2020 Q3 | -32.94 Million EUR | 77.44% |
| 2020 Q2 | -146.05 Million EUR | -61.64% |
| 2020 Q1 | -90.35 Million EUR | -231.95% |
| 2020 FY | -39.54 Million EUR | -157.75% |
| 2020 Q4 | -39.54 Million EUR | -20.02% |
| 2019 Q1 | 88.19 Million EUR | 24.81% |
| 2019 Q3 | 65.91 Million EUR | 22.5% |
| 2019 Q4 | 68.47 Million EUR | 3.88% |
| 2019 FY | 68.47 Million EUR | -3.09% |
| 2019 Q2 | 53.81 Million EUR | -38.98% |
| 2018 Q1 | 85.43 Million EUR | 12.54% |
| 2018 Q4 | 70.66 Million EUR | -2.59% |
| 2018 Q3 | 72.53 Million EUR | -23.8% |
| 2018 FY | 70.66 Million EUR | -6.92% |
| 2018 Q2 | 95.18 Million EUR | 11.42% |
| 2017 Q1 | 82.73 Million EUR | 1.89% |
| 2017 FY | 75.91 Million EUR | -6.51% |
| 2017 Q3 | 85.26 Million EUR | 1.37% |
| 2017 Q2 | 84.1 Million EUR | 1.66% |
| 2017 Q4 | 75.91 Million EUR | -10.96% |
| 2016 Q4 | 81.19 Million EUR | -9.33% |
| 2016 Q3 | 89.55 Million EUR | -9.78% |
| 2016 FY | 81.19 Million EUR | -5.55% |
| 2016 Q2 | 99.26 Million EUR | 0.66% |
| 2016 Q1 | 98.61 Million EUR | 14.7% |
| 2015 FY | 85.97 Million EUR | 14.76% |
| 2015 Q4 | 85.97 Million EUR | 22.51% |
| 2015 Q1 | 74.49 Million EUR | -0.56% |
| 2015 Q2 | 70.62 Million EUR | -5.19% |
| 2015 Q3 | 70.17 Million EUR | -0.64% |
| 2014 Q3 | 71.48 Million EUR | -6.02% |
| 2014 Q4 | 74.91 Million EUR | 4.8% |
| 2014 Q2 | 76.07 Million EUR | 5.91% |
| 2014 Q1 | 71.82 Million EUR | 0.02% |
| 2014 FY | 74.91 Million EUR | 4.33% |
| 2013 FY | 71.81 Million EUR | -27.03% |
| 2013 Q1 | 83.77 Million EUR | -14.88% |
| 2013 Q2 | 90.97 Million EUR | 8.6% |
| 2013 Q3 | 87.22 Million EUR | -4.12% |
| 2013 Q4 | 71.81 Million EUR | -17.68% |
| 2012 Q3 | 97.13 Million EUR | -4.5% |
| 2012 Q1 | 114.75 Million EUR | 8.92% |
| 2012 FY | 98.41 Million EUR | -6.6% |
| 2012 Q2 | 101.7 Million EUR | -11.38% |
| 2012 Q4 | 98.41 Million EUR | 1.32% |
| 2011 Q4 | 105.36 Million EUR | 54.67% |
| 2011 FY | 105.36 Million EUR | -2.08% |
| 2011 Q3 | 68.12 Million EUR | -41.94% |
| 2011 Q1 | 109.62 Million EUR | 1.88% |
| 2011 Q2 | 117.33 Million EUR | 7.04% |
| 2010 Q4 | 107.6 Million EUR | -14.92% |
| 2010 Q1 | 98.62 Million EUR | 13.06% |
| 2010 Q3 | 126.47 Million EUR | 0.35% |
| 2010 Q2 | 126.02 Million EUR | 27.79% |
| 2010 FY | 107.6 Million EUR | 23.35% |
| 2009 Q2 | 90.45 Million EUR | 409.83% |
| 2009 Q4 | 87.23 Million EUR | 289.73% |
| 2009 FY | 87.23 Million EUR | 330.73% |
| 2009 Q3 | -45.97 Million EUR | -150.83% |
| 2009 Q1 | -29.19 Million EUR | 22.78% |
| 2008 Q4 | -37.8 Million EUR | 0.0% |
| 2008 FY | -37.8 Million EUR | -153.81% |
| 2007 FY | -14.89 Million EUR | -12.68% |
| 2006 FY | -13.22 Million EUR | -153.76% |
| 2005 FY | 24.59 Million EUR | -10.98% |
| 2004 FY | 27.62 Million EUR | 164.27% |
| 2003 FY | -42.98 Million EUR | 55.34% |
| 2002 FY | -96.23 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 205.665% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 504.466% |
| SQZ Biotechnologies Company | -36.23 Million USD | 54.037% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 138.922% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -164.191% |
| Mesoblast Limited | 55.85 Million USD | 129.818% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1896.403% |
| Genus plc | 190.6 Million USD | 108.739% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 844.958% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 1472.12% |
| Marizyme, Inc. | 18.56 Million USD | 189.698% |
| ContraFect Corporation | -6.02 Million USD | -176.402% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 2549.412% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 12470.858% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 1541.542% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 842.831% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 402.732% |
| MultiCell Technologies, Inc. | 90.04 USD | 18498545.135% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -2169.278% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 228.658% |
| EV Biologics, Inc. | 1.36 Million USD | 1317.57% |
| Q BioMed Inc. | 4.06 Million USD | 510.245% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 154.513% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 2776.247% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 1752.847% |
| Biomind Labs Inc. | 711.4 Thousand USD | 2441.292% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 115.169% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 230.058% |
| Skye Bioscience, Inc. | -5.72 Million USD | -191.118% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 2036.202% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 12013.822% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 394.882% |
| IMV Inc. | 7.67 Million USD | 317.143% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 83937.52% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 856.41% |
| GB Sciences, Inc. | 1.74 Million USD | 1053.233% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -8962.616% |
| HST Global, Inc. | 96.79 Thousand USD | 17307.856% |
| CSL Limited | 10.52 Billion USD | 100.158% |
| Halberd Corporation | 144.72 Thousand USD | 11609.042% |
| Enzolytics Inc. | 981.65 Thousand USD | 1796.725% |
| Resverlogix Corp. | 6.45 Million USD | 358.193% |
| Affymax, Inc. | -5.59 Million USD | -197.588% |
| SYBLEU INC | 473.71 Thousand USD | 3616.046% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -2374.561% |
| argenx SE | -2.02 Billion USD | 99.179% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 138.348% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 64.571% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 714.927% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -88.418% |
| AVAX Technologies, Inc. | -5.9 Million USD | -182.152% |
| Zenith Capital Corp. | 10.06 Thousand USD | 165600.795% |
| Genscript Biotech Corporation | -1.06 Billion USD | 98.431% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 8410.05% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 798.062% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 10224.674% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 127.51% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 933.053% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -548.085% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 4730.397% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 182.146% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -90826.957% |
| BioStem Technologies, Inc. | 4.47 Million USD | 472.45% |
| ONE Bio Corp. | 9.04 Million USD | 284.247% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 8376.109% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -1271350.382% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 8176.929% |
| Agentix Corp. | 37.63 Thousand USD | 44361.38% |
| LadRx Corporation | -2.03 Million USD | -717.886% |
| Cell Source, Inc. | 9.23 Million USD | 280.417% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -81515.053% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2722.302% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2722.302% |
| NovAccess Global Inc. | 2.17 Million USD | 864.575% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 335.555% |
| Itoco Inc. | 228.3 Thousand USD | 7395.504% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 12348.049% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 436.01% |
| Kadimastem Ltd | -253.1 Thousand USD | -6480.746% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 4244.84% |
| CytoDyn Inc. | 20.26 Million USD | 182.203% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -2574243.122% |
| Mobile Lads Corp. | 484.23 Thousand USD | 3539.674% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -179608.556% |
| Qrons Inc. | 351.42 Thousand USD | 4839.533% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 316.143% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -6572.542% |
| Rebus Holdings, Inc. | 305 Thousand USD | 5560.984% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 473.702% |
| International Stem Cell Corporation | 2.59 Million USD | 743.089% |
| Bioxytran, Inc. | 1.89 Million USD | 977.133% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 26786.748% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 863.721% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 585.032% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 294.739% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 2255.818% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -1232.48% |
| Neutra Corp. | 52.18 Thousand USD | 32015.994% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -569.184% |
| PureTech Health plc | -167.19 Million USD | 90.038% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -6700.921% |
| IXICO plc | -4.44 Million USD | -274.748% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 226.0% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 130.366% |
| CSL Limited | 10.52 Billion USD | 100.158% |
| Cellectis S.A. | -43.81 Million USD | 61.989% |